Soy Protein Study Generates New Findings in Cholesterol
Reduction
New findings also in metabolic syndrome, clinical trials
recruitment
By Lynn Schultz-Writsel School of
Nursing
The Beneficial Effects of Soy Trial, a Baltimore-based
randomized controlled study of dietary soy, has yielded an
array of results pertaining to cholesterol reduction,
metabolic syndrome and recruitment for clinical trials. The
multidisciplinary study team, led by Jerilyn K. Allen, a
Johns Hopkins School of
Nursing researcher and lead investigator, reported its
findings this month in two journals — Menopause
and Ethnicity and Disease — and at the
American Heart Association 2006 Scientific Sessions.
In the study now appearing online in Menopause,
Allen and co-authors report that among their BEST study
group — 216 healthy postmenopausal African-American
and white women with moderately elevated low-density
lipoprotein cholesterol levels — those who received
isolated soy protein containing isoflavones experienced a
significant decrease in total cholesterol, LDL cholesterol
and lipoprotein particles. LDL levels decreased by an
average of 3.3 percent, LDL particles decreased by 5.6
percent, and beneficial high-density lipoprotein
cholesterol increased 4.4 percent. Noting that because
lipoprotein levels often increase as a consequence of
menopause, Allen cautions that while soy protein alone will
not lower cholesterol with the same effectiveness as
medications, "the modest effects of soy protein on LDL
cholesterol and LDL particle number may be beneficial for
heart health in postmenopausal women who do not require
statins or other medications to control their levels."
At the American Heart Association meeting, Allen and
School of Nursing co-authors Sarah Szanton, Kathleen
Lindenstruth and Carol Curtis reported additional BEST
study findings on factors associated with cardiovascular
disease. In "Effect of Metabolic Syndrome on Lipoprotein
Subclass Particle Size and Concentration in Postmenopausal
Women," the investigators reported on their evaluations of
women in the study with metabolic syndrome, a clustering of
at least three cardiovascular disease risk factors: high
blood pressure, high triglycerides, low levels of HDL
cholesterol (good cholesterol), high glucose or abdominal
obesity (large waist measurement). When compared to women
in the study without the syndrome, those with metabolic
syndrome had lower levels of high-density lipoprotein
cholesterol and higher levels of triglycerides without
significant differences in total cholesterol. However,
there were significant differences in major lipoprotein
subclass measures, showing that women with metabolic
syndrome had smaller mean LDL size, higher LDL particle
concentration and smaller mean HDL size, all factors
putting them at increased risk for cardiovascular
disease.
During the study, investigators also compiled data on
recruitment into the clinical trial. Published this month
in Ethnicity and Disease, Lindenstruth's analysis —
"Recruitment of African-American and White Postmenopausal
Women Into Clinical Trials: The Beneficial Effects of Soy
Trial Experience" — shows that African-American and
white women differed significantly in their response to
various forms of mass media and personalized techniques
employed to recruit participation in the clinical trial.
The most effective mechanism for recruiting
African-American women was direct mail (52 percent),
followed by radio (15 percent); newspapers were less
effective. Conversely, white women responded best to
newspaper ads (36 percent), followed by direct mail (32
percent); radio was less effective. These strategies were
more effective than personalized techniques — health
fairs, provider referrals, newsletters and churches.
The BEST study was funded by the National Heart, Lung
and Blood Institute to determine the effects of soy on
lipids, lipoproteins and lipoprotein subclasses in a sample
of African-American and white postmenopausal women. The
women in the study had low-density lipoprotein cholesterol
elevations that could increase their lifetime risk for
cardiovascular disease but would not qualify them for
definitive pharmacotherapy under current guidelines.
The secondary aims of the study were to assess the
impact of soy on menopausal quality of life, including
menopausal symptoms, and to examine racial/ethnic
differences in quality of life, acceptability and adherence
to the soy supplementation.
GO TO DECEMBER 4,
2006
TABLE OF CONTENTS.
GO TO THE GAZETTE
FRONT PAGE.
|